Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
PaperCitations, authors & open-access status
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1,135 citations, 2021 year and closed oa status.
1,135
Citations
2021
Year
closed
OA Status